To evaluate the role of SNAI2 in the control of EMT characteristics and resistance to fulvestrant, we performed gene knockdown studies with specific siRNA targeting SNAI2 in the two fulvestrant-resistant breast cancer cell models. This evidence concerns the gene SNAI2 and breast carcinoma.